Annovis Bio, Inc.(ANVS)

$1.69—

Chart

Annovis Bio, Inc.(ANVS)

NYSE

$1.69—

Chart Studio

ANVS(ANVS)

ANVS

Overview Fair Value Stream Notebook Intel Chart History Fundamentals TTM Earnings Analysts News Financials Insiders Institl.DCF Peers

Q4 2026 EPS Estimate

$-0.30

Nov 11, 2026

FY2029E EPS$0.64

FY2030E EPS$4.08

Analyst Sentiment

Wall St. Consensus

Buy

9 analysts·Limited coverage

Score

7 Buy (78%)2 Hold (22%)0 Sell (0%)

Rating Breakdown

Strong Buy

00%

Buy

778%

Hold

222%

Sell

00%

Strong Sell

00%

Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.

Price Target Expectations

Bear

$21.00

+1142.6%

Consensus

$26.00

+1438.5%

Bull

$30.00

+1675.1%

12-Month Target Range9 analysts

$21.00$26.00$30.00

Current $1.69Consensus

Current Price

$1.69

Upside to Consensus

$24.31

Price targets are 12-month analyst forecasts. Actual results depend on earnings, market conditions, and sector trends.

Earnings & Revenue Estimates

Forward Growth Estimates (YoY)

FY2027

Rev+52.48%

EPS—

FY2028

Rev+202.78%

EPS—

FY2029

Rev+488.63%

EPS—

Raw consensus estimates (low / average / high) from covering analysts.

Annual

Metric	FY2026E	FY2027E	FY2028E	FY2029E	FY2030E
Revenue Avg	$11M	$17M	$51M	$297M	$619M
Low	$11M	$17M	$51M	$297M	$619M
High	$11M	$17M	$51M	$297M	$619M
EBITDA Avg	$-24M	$-16M	$-28M	$19M	$109M
Low	$-24M	$-16M	$-37M	$19M	$109M
High	$-24M	$-16M	$-18M	$19M	$109M
EBIT Avg	$-28M	$-19M	$-31M	$17M	$107M
Low	$-28M	$-19M	$-40M	$17M	$107M
High	$-28M	$-19M	$-21M	$17M	$107M
Net Income Avg	$-29M	$-20M	$-31M	$13M	$84M
Low	$-29M	$-20M	$-41M	$13M	$84M
High	$-29M	$-20M	$-21M	$13M	$84M
EPS Avg	$-1.41	$-0.97	$-1.51	$0.64	$4.08
Low	$-1.41	$-0.97	$-1.99	$0.64	$4.08
High	$-1.41	$-0.97	$-1.04	$0.64	$4.08
Analysts (Rev / EPS)	3 / 2	3 / 2	3 / 2	1 / 1	2 / 1

Quarterly

Metric	Q3 2026	Q4 2026	Q1 2027	Q2 2027	Q3 2027	Q4 2027	Q1 2028	Q2 2028
Revenue Avg	—	—	—	—	—	—	$11M	$11M
Low	—	—	—	—	—	—	$11M	$11M
High	—	—	—	—	—	—	$11M	$11M
EBITDA Avg	—	—	—	—	—	—	$-2M	$-2M
Low	—	—	—	—	—	—	$-2M	$-2M
High	—	—	—	—	—	—	$-2M	$-2M
EBIT Avg	—	—	—	—	—	—	$-2M	$-2M
Low	—	—	—	—	—	—	$-2M	$-2M
High	—	—	—	—	—	—	$-2M	$-2M
Net Income Avg	$-11M	$-9M	$-9M	$-9M	$-9M	$-9M	$-2M	$-2M
Low	$-11M	$-9M	$-9M	$-9M	$-9M	$-9M	$-2M	$-2M
High	$-11M	$-9M	$-9M	$-9M	$-9M	$-9M	$-2M	$-2M
EPS Avg	$-0.30	$-0.23	$-0.25	$-0.23	$-0.24	$-0.24	$-0.06	$-0.06
Low	$-0.30	$-0.23	$-0.25	$-0.23	$-0.24	$-0.24	$-0.06	$-0.06
High	$-0.30	$-0.23	$-0.25	$-0.23	$-0.24	$-0.24	$-0.06	$-0.06
Analysts (Rev / EPS)	— / 1	— / 1	— / 1	— / 1	— / 1	— / 1	1 / 1	1 / 1

Earnings Surprises

Recent Analyst Actions

Oct 16, 2024H.C. Wainwright

H.C. Wainwright Reiterates Buy Rating on Annovis Bio Inc. (ANVS)

Target:$30.00

+240.1%from $8.82

Aug 13, 2024EF Hutton

Annovis Bio initiated with a Buy at EF Hutton

Target:$21.00

+166.8%from $7.87

Apr 30, 2024Canaccord Genuity

Annovis Bio price target lowered to $26 from $36 at Canaccord

Target:$26.00

+257.1%from $7.28

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance